Hyperhomocysteinaemia-induced cardiovascular changes in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 8, 2008, Pages 949-956

  Resstel, Leonardo B M ^a   De Andrade, Claudia R ^a   Haddad, Renato ^b   Eberlin, Marcos N ^b   De Oliveira, Ana M ^c   Corrêa, Fernando M A ^a,d  

^a Department of Obstetrics and Gynecology School of Medicine Universida de Estadual de Campinas   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d NONE   (Brazil)

Author keywords

Arterial pressure; Baroreflex; Heart rate; Hyperhomocysteinemia; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; ATENOLOL; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; ANTIHYPERTENSIVE AGENT; CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HEART RATE; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; REST; SYMPATHETIC TONE; ADRENERGIC SYSTEM; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INNERVATION; PATHOPHYSIOLOGY; TACHYCARDIA; VASCULAR RESISTANCE; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; HEART RATE; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; NITROPRUSSIDE; PHENYLEPHRINE; RATS, WISTAR; SYMPATHETIC NERVOUS SYSTEM; TACHYCARDIA; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 46749156341     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04940.x     Document Type: Article

References (49)

1. Kawashiri M, Kajinami K, Nohara A et al. Plasma homocysteine level and development of coronary artery disease. Coron. Artery Dis. 1999 10 : 443 7.
2. 12, folate, and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000 18 : 139 46.
3. Cooke GE, Eaton GM, Whitby G et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J. Am. Coll. Cardiol. 2000 36 : 509 16.
4. Parisi AF. Clinical trials of coronary revascularization for chronic stable angina: Medical treatment versus coronary revascularization. Curr. Opin. Cardiol. 2000 15 : 275 80.
5. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J. Vasc. Surg. 1999 29 : 8 19.
6. Mansoor MA, Bergmark C, Haswell SJ et al. Correlation between plasma total homocysteine and copper in patients with peripheral vascular disease. Clin. Chem. 2000 46 : 385 91.
7. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand. J. Clin. Lab. Invest. 2000 60 : 491 9.
8. Linnebank M, Montenarh M, Kolsch H et al. Common genetic variants of homocysteine metabolism in ischemic stroke: A case-control study. Eur. J. Neurol. 2005 12 : 614 18.
9. Nygard O, Refsum H, Ueland PM. Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am. J. Clin. Nutr. 1998 67 : 263 70.
10. Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler. Thromb. Vasc. Biol. 1999 19 : 1899 904.
11. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997 337 : 230 6.
12. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin. Thromb. Hemost. 2000 26 : 281 9.
13. Malinow MR, Levenson J, Giral P et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995 114 : 175 83.
14. Rolland PH, Friggi A, Barlatier A et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995 91 : 1161 74.
15. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997 96 : 1745 9.
16. Fiorina P, Lanfredini M, Montanari A et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am. J. Hypertens. 1998 11 : 1100 7.
17. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: A randomized controlled trial. J. Intern. Med. 2002 252 : 497 503.
18. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr. Hypertens. Rep. 2003 5 : 26 31.
19. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am. J. Clin. Nutr. 2000 72 : 315 23.
20. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual? Arch. Intern. Med. 2000 160 : 422 34.
21. McCully KS, Carvalho AC. Homocysteine thiolactone, N- homocysteine thiolactonyl retinamide, and platelet aggregation. Res. Commun. Chem. Pathol. Pharmacol. 1987 56 : 349 60.
22. Ossani GP, Fischer PA, Caram SG, Dominguez GN, Monserrat AJ, Masnatta LD. Mild hyperhomocysteinemia promotes renal hemodynamic dysfunction without histopathologic changes in adult rats. Kidney Int. 2004 66 : 1866 72.
23. Miao CY, Villeneuve N, Brunel-Jacquemin C et al. Chronic mild hyperhomocysteinemia induces aortic endothelial dysfunction but does not elevate arterial pressure in rats. J. Vasc. Res. 2005 42 : 148 56.
24. Dudman NP, Wilcken DE. Homocysteine thiolactone and experimental homocysteinemia. Biochem. Med. 1982 27 : 244 53.
25. Reddy GS, Wilcken DE. Experimental homocysteinemia in pigs: Comparison with studies in sixteen homocystinuric patients. Metabolism 1982 31 : 778 83.
26. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 1997 272 : 1935 42.
27. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: Implications for atherosclerosis. Circ. Res. 2000 87 : 45 51.
28. de Andrade CR, Fukada SY, Olivon VC et al. Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur. J. Pharmacol. 2006 543 : 83 91.
29. Resstel LB, Fernandes KB, Correa FM. Medial prefrontal cortex modulation of the baroreflex parasympathetic component in the rat. Brain Res. 2004 1015 : 136 44.
30. Head GA, McCarty R. Vagal and sympathetic components of the heart rate range and gain of the baroreceptor-heart rate reflex in conscious rats. J. Auton. Nerv. Syst. 1987 21 : 203 13.
31. Su DF, Cerutti C, Barres C et al. Arterial baroreflex control of heart period is not related to blood pressure variability in conscious hypertensive and normotensive rats. Clin. Exp. Pharmacol. Physiol. 1992 19 : 767 76.
32. Resstel LB, Correa FM. Pressor and tachycardic responses evoked by microinjections of l-glutamate into the medial prefrontal cortex of unanaesthetized rats. Eur. J. Neurosci. 2005 21 : 2513 20.
33. Korner PI, Shaw J, West MJ, Oliver JR. Central nervous system control of baroreceptor reflexes in the rabbit. Circ. Res. 1972 31 : 637 52.
34. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N. Engl. J. Med. 1995 332 : 328 9.
35. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995 274 : 1526 33.
36. Wocial B, Berent H, Kostrubiec M, Kuczynska K, Kuch-Wocial A, Nieweglowska N. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Pressure 2002 11 : 201 5.
37. Fu WY, Dudman NP, Perry MA, Wang XL. Homocysteine attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002 161 : 169 76.
38. Robin S, Courderot-Masuyer C, Nicod L, Jacqueson A, Richert L, Berthelot A. Opposite effect of methionine-supplemented diet, a model of hyperhomocysteinemia, on plasma and liver antioxidant status in normotensive and spontaneously hypertensive rats. J. Nutr. Biochem. 2004 15 : 80 9.
39. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am. J. Hypertens. 2002 15 : 157 63.
40. Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 1997 61 : 1205 15.
41. De Vriese AS, Blom HJ, Heil SG et al. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 2004 109 : 2331 6.
42. Heil SG, De Vriese AS, Kluijtmans LA, Mortier S, Den Heijer M, Blom HJ. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation. Cell. Mol. Biol. 2004 50 : 911 16.
43. Mayer O, Filipovsky J, Dolejsova M, Cífková R, Simon J, Bolek L. Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. J. Hum. Hypertens. 2006 20 : 267 71.
44. Tayama J, Munakata M, Yoshinaga K, Toyota T. Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients. Hypertens. Res. 2006 29 : 403 9.
45. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 1992 12 : 279 98.
46. Grassi G, Seravalle G, Giannattasio C et al. Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction. Am. J. Cardiol. 1999 84 : 525 9.
47. Lohmeier TE. The sympathetic nervous system and long-term blood pressure regulation. Am. J. Hypertens. 2001 14 : 147S 54S.
48. Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002 282 : R1044 53.
49. Lohmeier TE, Dwyer TM, Hildebrandt DA et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005 46 : 1194 200.